台灣癌症防治網

荷爾蒙療法臨床試驗摘要

Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms:a double-blind randomized non-inferiority trial
The Effect of Tibolone in Older Postmenopausal Women
Breast cancer and hormone-replacement therapy in the Million Women study
Endometrial cancer and hormone-replacement therapy in the Million Women study

肺癌臨床試驗摘要

EGFR mutation predicts response to gefitinib in patients with NSCLC
TRIBUTE:a phase III trail of erlotinib hydrochloride(OSI-774)combined with carboplastin and paclitaxed chemotherapy in advanced NSCLC

乳癌臨床試驗摘要

A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first line therapy for locally recurrent or metastatic breast cancer
Trastuzumab in adjuvant breast cancer
Effective and safety of Trastuzumab combined with Docetaxel in Patients with human epidermal growth factor receptor 2- positive metastatic breast cancer administrated as first line treatment
Herceptin in adjuvant breast cacner
Effective and safety of Trastuzumab as single agent in first line treatment of Her2-overexpressing metastatic breast cancer
Multinational study of efficacy and safety of humanized anti-Her2 monoclonal antibody in women who have Her2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
Use of chemotherapy plus a monoclonal antibody againt her2 for metastatic breast cancer that overexpresses her2
Significantly higher pathology complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin chemotherapy: Results a randomized trial in human epidermal growth facter receptor-2 positive breast cancer950127
Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase Ⅲ study conducted by the Hellenic Copperative Oncology Group950106
Phase Ⅲ trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer
Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast Cancer
Adjuvant Docetaxel for Node-Positive Breast Cancer
Docetaxel and Doxorubicin Compared With Doxorubicin and Cyclophosphamide as First-Line Chemotherapy for Metastatic Breast Cancer: Results of a Randomized, Multicenter, Phase III Trial

大腸直腸癌臨床試驗摘要

Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC)
Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC)
Impact on quality of life of adding cetuximab to irinotecan in patients who have failed prior oxaliplatin-based therapy
Infusion-related reactions (IRR) associated with cetuximab plus irinotecan treatment in patients with irinotecan-resistant metastatic colorectal cancer (mCRC)
Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): Pharmacokinetic (PK), Pharmacodynamic (PD) and efficacy data.
Randomized Phase III trial of cetuximab monotherapy plus best supportive care (BSC) versus BSC alone in patients with pretreated metastatic epidermal growth factor receptor (EGFR)-positive colorectal carcinoma: A trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) and the Australasian Gastro-Intestinal Trials Group (AGITG)
Oxaliplatin/5FU/LV in the adjvvant treatment of stage II and stage III colon cancer: efficacy results with a median follow-up of 4 years
A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Results of NSABP Protocol C-07
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200.
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
High-dose Bevacizumab in Combination with FOLFOX4 Improve Survival in Patients with Previously
Bevacizumab plus Irinotecan, Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Capecitabine (Xeloda) vs bolus 5-FU/Leucovorin (LV) as adjuvant therapy for colon cancer
A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer

胃癌臨床試驗摘要

Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer
Phase II Study of Oxaliplatin, Fluorouracil, and Folinic Acid in Locally Advanced or Metastatic Gastric Cancer Patients

前列腺癌臨床試驗摘要

Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer

白血病臨床試驗摘要

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for Chronic Lymphocytic Leukemia
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory Chronic Lymphocytic Leukemia

淋巴瘤臨床試驗摘要

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte950505
CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

胰臟癌臨床試驗摘要

Erlotinib Improves Survival When Added to Gemcitabine in Patients with Advanced Pancreatic Cancer. A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG)

其他臨床試驗摘要

Anagrelide, a Therapy for Thrombocythemic States:Experience in 577 Patient

贊助捐款 勸募公告 財務報表 醫療相關

回頂部